The 2024 agenda will be confirmed soon. The 2023 agenda can be found below.

*All times are in PDT


Fri 25

6:30PM -8:00PM

Welcome reception


Sat 26

8:00AM -8:10AM

Meeting objectives & introduction
Naval Daver & Andrew Wei

8:10AM -9:50AM

Session 1: New research perspectives in AML
Chairs: Ravi Majeti & Iannis Aifantis

  • Clonal Evolution in AML: Ravi Majeti
  • Predictors of transformation in CHIP and CCUS and ways to optimize prediction: Koichi Takahashi
  • Potential for early intervention in CHIP and CCUS: Uma Borate

Panel discussion

  • Familial leukemia predispositions: understanding, identifying, and monitoring: Courtney DiNardo
  • Harnessing epigenetic information in AML to identify novel potential therapeutic approaches: Maria “Ken” Figueroa
  • Deconvoluting clonal and cellular architecture in IDH-mutant AML: Iannis Aifantis
  • Ancestry-inclusive consideration of AML genomics: Ann-Kathrin Eisfeld

Panel discussion

9:50AM -10:00AM


10:00AM -11:55AM

Session 2: Controversies in AML
Chairs: Gail Roboz & Naval Daver

  • Improving intensive chemotherapy approaches in frontline AML: Tapan Kadia
  • Which patients should have allogeneic transplants in 2023?: Charles Craddock
  • Intensive chemo or HMA + VEN intermediate for younger AML patients?: Eunice Wang
  • Keeping AML patients in remission – maintenance vs transplant: Gail Roboz

Panel discussion

  • Optimizing therapy in secondary AML and optimal use of CPX-351: Tara Lin
  • Clinical approaches for IDH-mutated AML: Eytan Stein
  • Frontline approaches for FLT3-mutant AML: Harry Erba
  • Current approaches for relapsed FLT3-mutant AML: Jessica Altman

Panel discussion

11:55AM -1:15PM

Session 3: New frontiers in MRD for AML clinical practice
Chairs: Richard Stone & Marina Konopleva

  • Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
  • Value of MRD assessment in non-intensive regimens in AML: Farhad Ravandi-Kashani
  • Value of MRD assessment in intensive regimens in AML: Maximillian Stahl
  • MRD as a clinical endpoint in clinical trials: Roland Walter
  • Applying MRD techniques in FLT3 mutated AML – are we able to use MRD as an endpoint in FLT3 AML?: Alexander Perl
  • MRD-directed interventions: Andrew Wei

Panel discussion

1:15PM -2:15PM


2:15PM -3:35PM

Session 4: BPDCN & MDS/MPN + CMML
Chairs: Naveen Pemmaraju & Mrinal Patnaik

  • Updates in diagnosis, pathogenesis and future directions in BPDCN: Naveen Pemmaraju
  • Current and new directions for accelerated/BP/transformed MPN: Anand Patel
  • VEXAS: a new entity: Emma Groarke
  • Future targets and drug development in CMML: Mrinal Patnaik
  • Bench to bedside in MPNs: CALR and targeting CALR: Naveen Pemmaraju
  • Novel targeted Agents in MPNs: Raajit Rampal

Panel discussion

3:35PM -3:45PM


3:45PM -6:00PM

Session 5: Novel targets, combinations and treatments in AML
Part 1 – new AML therapies and limitations
Chairs: Andrew Wei and Eunice Wang

Keynote talk
History of development and future directions for FLT3 inhibitors in AML: Mark Levis

New AML therapies and limitations

  • Optimizing doublet and triplet combinations in AML – improving efficacy while maintaining safety: Naval Daver
  • Uproleselan in frontline and R/R AML: Geoffrey Uy
  • TP53 treatment strategies in AML: Thomas Cluzeau

Panel discussion

  • Menin inhibitors in AML: Ghayas Issa
  • Mechanisms of resistance and combination approaches with menin inhibitors in AML: Eytan Stein
  • Targeting resistance to venetoclax-based therapies: Marina Konopleva
  • Resistance to FLT3 inhibitors: Catherine Smith

Panel discussion

Day 1 ends


Sun 27

8:30AM -8:35AM

Introduction to Day 2
Naval Daver & Andrew Wei

8:35AM -9:20AM

Session 6: Special session on regulatory endpoints in AML
Chairs: Courtney DiNardo & Mark Levis

  • The FDA’s perspective on regulatory endpoints in AML: Joseph Wynne
  • A clinical investigator’s perspective on endpoints and drug development in AML: Naval Daver

Panel discussion including Kelly Norsworthy

9:20AM -10:20AM

Session 7: Novel targets, combinations, and treatments in AML
Part 2 – what do we know about drug resistance?
Chairs: Charles Craddock & Courtney DiNardo

  • Genomic landscape and prognostic implications of TP53 mutations in AML: Sanam Loghavi
  • p53 reactivators and magrolimab in TP53-mutant MDS/AML: David Sallman
  • Novel pro-survival combinations: Andrew Wei
10:20AM -10:40AM


10:40AM -12:25PM

Session 8: Transplant and immunotherapies in AML
Chairs: Charles Craddock & David Sallman

  • Vedolizumab for prophylaxis and treatment of acute GvHD post-alloSCT: Yngvar Fløisand
  • Updates in the use of post-transplant cyclophosphamide: Nelli Bejanyan
  • Which patients with AML in MRD+ CRi should be transplanted?:Roland Walter
  • Lessons from the MORPHO trial: Mark Levis
  • Novel T-cell approaches for R/R AML (excluding CAR-T): Nelli Bejanyan
  • Early phase CAR-T and NK cell trials for R/R AML and MDS: David Sallman

Panel discussion

12:25PM -12:30PM

Meeting conclusions & final remarks